{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/adverse-drug-reactions/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0974ec45-5b01-515b-b02e-5cad23aacea1","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field ca47fee3-0b16-4956-9d3d-0907d68fda62 --><h2>Changes</h2><!-- end field ca47fee3-0b16-4956-9d3d-0907d68fda62 -->","summary":null,"htmlStringContent":"<!-- begin item d4849502-097f-43b4-a126-d87bf0493073 --><!-- begin field 89688a7b-e5b8-44da-ac71-ee0d17e21281 --><p><strong>March 2017 </strong>— reviewed. A literature search was conducted in March 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. The Medicines and Healthcare Products Regulatory Agency (MHRA) no longer request that all suspected adverse drug reactions (ADRs) in children are reported; the advice on which suspected ADRs to report in children is now the same as for adults. This new guidance is as a result of feedback that the previous guidelines (asking all suspected ADRs in children to be reported) were impractical and deterred reporting (MHRA, 2015). </p><!-- end field 89688a7b-e5b8-44da-ac71-ee0d17e21281 --><!-- end item d4849502-097f-43b4-a126-d87bf0493073 -->","topic":{"id":"5891f47f-d14e-5ade-b43e-09ab2ee894c3","topicId":"fb7af4be-ae9d-4213-b2ca-ca17ddb868c1","topicName":"Adverse drug reactions","slug":"adverse-drug-reactions","lastRevised":"Last revised in March 2017","chapters":[{"id":"78737b02-a5d5-5686-924f-3bd67a984373","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3124c32f-664e-57ef-805a-95067102ad32","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0974ec45-5b01-515b-b02e-5cad23aacea1","slug":"changes","fullItemName":"Changes"},{"id":"6474141f-1642-5857-9d25-033f3b7503f0","slug":"update","fullItemName":"Update"}]},{"id":"5bad1097-961b-5653-8f9b-6456f05b7836","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6be883ff-72cf-54e9-b064-31f4df584e67","slug":"goals","fullItemName":"Goals"},{"id":"c6cc81cc-134f-5d98-b79c-967bf65bddd3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"95dab13c-419c-5de3-b7fd-95118f8b48e5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d675aba3-9d84-5b1a-9c2b-79cc7bcab6c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd63cb73-82b3-5c83-bea6-b82fa98f7888","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"977ca222-407c-5643-a723-eeee2b2f6c0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"26252f90-7908-554e-8535-a49168c8bf4a","slug":"definition","fullItemName":"Definition"},{"id":"68cfd9ca-f6d9-582b-a898-39bd0927455f","slug":"categorization-of-adrs","fullItemName":"Categorization of ADRs"},{"id":"2bf3267e-f0ed-5301-b659-3a0d290262bc","slug":"health-financial-implications-of-adrs","fullItemName":"Health and financial implications of ADRs"},{"id":"804b9155-4dc6-574d-b5b3-3e320dd07967","slug":"monitoring-adverse-drug-reactions","fullItemName":"Monitoring adverse drug reactions"}]},{"id":"753ee7eb-1c21-5cf5-8e2e-e0e3ebd8be4a","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d7dbb3f-b730-5e84-aea1-49ed9234a126","slug":"adverse-drug-reactions","fullItemName":"Scenario: Adverse drug reactions"}]},{"id":"95500d82-4a44-5f81-befc-15cfb88abd53","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"77a8b838-04cb-5545-affe-c92faa19e1bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dfa6f9b0-4f82-5b25-99fb-5ce802d731e8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f85a17d1-c7b8-5ebf-a80c-88c2f6c69eff","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5aee896a-ac4b-5a54-bde2-0577412d6418","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8054ea0e-276d-5167-818e-fec1d38114aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1a62db49-0d92-514d-9a4a-dfa05227ec25","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86d8d508-d776-5c0a-be24-6df70fb79006","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"241ac7c2-a506-58ef-b56c-7f1faf9ad5d3","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field dc90dfe2-3413-4064-b4a6-55e70776b11d --><h3>Previous changes</h3><!-- end field dc90dfe2-3413-4064-b4a6-55e70776b11d -->","summary":null,"htmlStringContent":"<!-- begin item cd9e22e7-aa2d-442a-a964-25cf16063953 --><!-- begin field e11e8468-94f9-471e-8c40-f4fb7e7ecd82 --><p><strong>March 2012 </strong>— minor update. The Yellow Card website URL has been changed to <a href=\"http://www.mhra.gov.uk/yellowcard\" data-hyperlink-id=\"9a8e38e4-1890-422f-99c9-a99300a55968\">www.mhra.gov.uk/yellowcard</a> in line with government policy to reduce the number of government domains. Links to this website have been updated throughout this topic. Issued in April 2012.</p><p><strong>December 2011 </strong>— revised. A literature search was conducted in October 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. No changes to clinical recommendations were made. However, information from several additional information nodes have been incorporated into the main nodes to improve clarity. Issued in January 2012.</p><p><strong>January 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>February to June 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>November 2003 </strong>— rewritten. Validated in March 2004 and issued in June 2004.</p><p><strong>November 2000 </strong>— reviewed. Validated in March 2001 and issued in June 2001.</p><p><strong>August 1997 </strong>— written.</p><!-- end field e11e8468-94f9-471e-8c40-f4fb7e7ecd82 --><!-- end item cd9e22e7-aa2d-442a-a964-25cf16063953 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}